- Previous Close
0.2999 - Open
0.3000 - Bid 0.2100 x 200
- Ask 0.3848 x 200
- Day's Range
0.2927 - 0.3082 - 52 Week Range
0.1800 - 1.7400 - Volume
318,650 - Avg. Volume
3,407,688 - Market Cap (intraday)
29.892M - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5300 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
www.fibrogen.comRecent News: FGEN
View More
Performance Overview: FGEN
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FGEN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FGEN
View MoreValuation Measures
Market Cap
29.89M
Enterprise Value
52.50M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.00
Price/Book (mrq)
--
Enterprise Value/Revenue
1.77
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-160.63%
Return on Assets (ttm)
-25.66%
Return on Equity (ttm)
--
Revenue (ttm)
29.62M
Net Income Avi to Common (ttm)
-153.1M
Diluted EPS (ttm)
-1.5300
Balance Sheet and Cash Flow
Total Cash (mrq)
50.48M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-150.77M